TenQ · fact sheet · filings current to · price as of
Amgen (AMGN)
A mixed picture - strengths and real weaknesses - 22 of 36 checks passed.
Latest close : $437.23, -1.6% on the day; -1.6% from the 52-week high. Refreshed every trading night.
Full analysis: report · all charts. Financial statements are computed from SEC EDGAR XBRL filings, current to . The share price and everything built on it (market cap, multiples, yields, the Value and Trend checks) are refreshed every trading night; this page shows the close of . Not investment advice.
Key figures
| Share price (delayed close) | $437.23 |
| Market cap | $236.4B |
| 52-week range | $263.86 - $444.12 |
| P/E | 27.1x |
| P/E, own 11-year median | 17.9x |
| P/S | 6.2x |
| Free cash flow yield | 4.3% |
| Dividend yield | 2.2% |
| Revenue (TTM) | $38.1B |
| Net income (TTM) | $8.7B |
| Free cash flow (TTM) | $10.2B |
| Gross margin | 47.5% |
| Operating margin | 30.0% |
| Return on equity | 74.8% |
| Revenue growth (1y) | +9.1% |
| Revenue CAGR (3y) | +11.8% |
| Debt / equity | 4.90x |
| Cash & short-term investments | $14.0B |
| Shares outstanding | 540.6m (cover page of the latest filing, 2026-07-30) |
The score: 22 of 36 checks passed
Six chapters, six pass/fail checks each. Five are computed from the filings; Trend is price behaviour, and says so.
Is AMGN stock cheap or expensive right now?
Value · 1 of 6 checks passed. Expensive against its own history and its sector - you're paying up for what you get. chapter →
Is Amgen still growing?
Growth · 2 of 6 checks passed. Growth is weak or inconsistent - the trend, not the story, is the problem. chapter →
Does Amgen make real money?
Quality · 5 of 6 checks passed. Rare profitability: margins and returns on capital are well above its peers. chapter →
Can Amgen survive a bad year?
Health · 3 of 6 checks passed. Financially sound overall, with one or two things worth watching. chapter →
What does Amgen hand back to shareholders?
Shareholder returns · 5 of 6 checks passed. Owners are paid reliably and affordably, and the share count is not eroding their stake. chapter →
Which way is AMGN trending?
Trend analysis · 6 of 6 checks passed. The market agrees: the stock is in a healthy uptrend on every horizon. chapter →
Are insiders buying or selling AMGN?
Open-market buys: $0.00 · sells: $4M, across the recent Form 4 filings. detail →
Other pharma and chemicals we cover: Eli Lilly (LLY) · Johnson & Johnson (JNJ) · AbbVie (ABBV) · Merck (MRK) · Procter & Gamble (PG) · Abbott Laboratories (ABT) · every company →
Method: figures computed deterministically from SEC EDGAR XBRL (companyfacts, frames, financial-statement-and-notes datasets, Form 4); prices delayed end-of-day. Scores count transparent pass/fail checks. Missing data is shown as missing, never estimated. Last changed . © TenQ - cite with a link to this page.